Cargando…

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

Although immunotherapy has achieved impressive durable clinical responses, many cancers respond only temporarily or not at all to immunotherapy. To find novel, targetable mechanisms of resistance to immunotherapy, patient-derived melanoma cell lines were transduced with 576 open reading frames, or e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Punt, Simone, Malu, Shruti, McKenzie, Jodi A., Manrique, Soraya Zorro, Doorduijn, Elien M., Mbofung, Rina M., Williams, Leila, Silverman, Deborah A., Ashkin, Emily L., Dominguez, Ana Lucía, Wang, Zhe, Chen, Jie Qing, Maiti, Sourindra N., Tieu, Trang N., Liu, Chengwen, Xu, Chunyu, Forget, Marie-Andrée, Haymaker, Cara, Khalili, Jahan S., Satani, Nikunj, Muller, Florian, Cooper, Laurence J. N., Overwijk, Willem W., Amaria, Rodabe N., Bernatchez, Chantale, Heffernan, Timothy P., Peng, Weiyi, Roszik, Jason, Hwu, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979613/ https://www.ncbi.nlm.nih.gov/pubmed/33123754 http://dx.doi.org/10.1007/s00262-020-02748-9

Ejemplares similares

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
por: Mbofung, Rina M., et al.
Publicado: (2017)

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
por: Forget, Marie-Andrée, et al.
Publicado: (2015)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy
por: Forget, Marie-Andrée, et al.
Publicado: (2013)

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jieqing, et al.
Publicado: (2014)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

The role of transcription factor Runx2 in tumor infiltrating T cells
por: Mbofung, Rina, et al.
Publicado: (2013)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
por: Haymaker, Cara L, et al.
Publicado: (2015)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

Molecular and immune heterogeneity in synchronous melanoma metastases
por: Reuben, Alexandre, et al.
Publicado: (2015)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
por: Parra, Edwin R., et al.
Publicado: (2017)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
por: Fix, Samantha M, et al.
Publicado: (2022)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

RNA editing derived epitopes function as cancer antigens to elicit immune responses
por: Zhang, Minying, et al.
Publicado: (2018)

Absence of Grail promotes CD8(+) T cell anti-tumour activity
por: Haymaker, Cara, et al.
Publicado: (2017)

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
por: Im, Jin S., et al.
Publicado: (2016)

Mesenchymal Stem Cell Derived Extracellular Vesicles for Repairing the Neurovascular Unit after Ischemic Stroke
por: Davis, Courtney, et al.
Publicado: (2021)

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
por: Duke, Taylor C., et al.
Publicado: (2020)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators
por: Qin, Yong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8bnt3mt4kr3n26ms163s6gcqbf